Registered securities include 241,667 shares issuable on conversion
By Devika Patel
Knoxville, Tenn., July 9 – Amarantus Bioscience Holdings, Inc. arranged a $2 million direct sale of its series G convertible preferred stock, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.
The company will sell 435 preferreds.
The registration includes up to 241,667 common shares issuable upon conversion of the preferreds and up to 3 million common shares that may be issued as a conversion premium.
The biotechnology company is based in Sunnyvale, Calif.
| Issuer: | Amarantus Bioscience Holdings, Inc.
|
| Issue: | Series G convertible preferred stock
|
| Amount: | $2 million
|
| Preferreds: | 435
|
| Warrants: | No
|
| Pricing date: | July 9
|
| Stock symbol: | Nasdaq: AMBS
|
| Stock price: | $0.05 at close July 8
|
| Market capitalization: | $36.75 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
